Healthcare / Biotech / BioTech / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Addgene / amazon / Amyotrophic Lateral Sclerosis / Anika Therapeutics / Autolus Therapeutics / Berkshire Hathaway / Brainstorm Cell Therapeutics / CAR-T / Charlie Baker / chronic cluster headaches / Cingal / Decibel Therapeutics / Deval Patrick / dry age-related macular degeneration / Eidos Therapeutics / Elizabeth Holmes / Emulate / Foundation Medicine / fremanezumab / investing / IPO / Joanne Kamens / JPMorgan Chase / Kallyope / Life Sciences / Migraine / Ortho Dermatologics / plaque psoriasis / Puma Biotechnology / Purdue Pharma / Ramesh Balwani / Renaissance Capital / right to try / Robert Gadimian / Roche / Sarepta Therapeutics / Solid Biosciences / startups / Stealth BioTherapeutics / Teva Pharmaceutical / Theranos / Tim Draper / Valeant Pharmaceuticals / Venture Capital / Ziopharm Oncology

Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More

Posted on: Jun 22, 2018   |   Posted by: Biotech Mag

Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More

Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed...

Continue reading ...